Feasibility of a Diet Intervention for Juvenile Arthritis
NCT06474546
Recruiting
Families of children with arthritis are highly interested in the benefits of diet to improve their child's disease and future health outcomes. Previous research shows that the germs - bacteria and other organisms - that live in the intestines (gut microbiome) are important to how well immune systems work, and that what people eat changes their gut microbiome. The investigators want to study whether a certain diet - based on the principles of the Mediterranean Diet - will improve arthritis for ch... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
06/05/2025
Locations: University of Manitoba, Winnipeg, Manitoba +6 locations
Conditions: Arthritis, Juvenile, Arthritis, Childhood, Juvenile Idiopathic Arthritis
Register for Updates
Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes
NCT03455868
Recruiting
Background: Bone fragility is a complication of type 2 diabetes. Diabetes treatments may ameliorate or deteriorate bone fragility in this population. Bariatric surgery is gaining in popularity in people with type 2 diabetes and may impact bone health. Objectives: To evaluate the impact of the most popular bariatric procedure worldwide (sleeve gastrectomy (SG)) on vBMD by QCT in patients with type 2 diabetes; Secondary aims: (1) to identify the determinants of vBMD after bariatric surgery in pati... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/05/2025
Locations: The Research Institute of the McGill University Health Centre, Montréal, Quebec +2 locations
Conditions: Bariatric Surgery, Bone Health, Obesity, Morbid, Diabetes Mellitus, Type 2
Register for Updates
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +87 locations
Conditions: Intracerebral Hemorrhage
Register for Updates
Safety and Efficacy of TSHA-102 in Adolescent and Adult Females With Rett Syndrome (REVEAL Adult Study)
NCT05606614
Recruiting
The REVEAL Adult Study is a multi-center, Phase 1/2 open-label, dose-escalation study of TSHA-102, an investigational gene therapy, in adult females with Rett syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is estimated to be up to 63 months.
Gender:
FEMALE
Ages:
12 years and above
Trial Updated:
06/05/2025
Locations: UC San Diego, La Jolla, California +5 locations
Conditions: Rett Syndrome
Register for Updates
Online COgnitive Behavioural Therapy for Sleep and Mental Health for Older Adults With Insomnia and Subjective Cognitive Complaints
NCT06032377
Recruiting
The goal of this randomized controlled clinical trial is to assess a novel cognitive-behavioral program for sleep and mental health using a multidomain web platform (eCBTi+) in participants with insomnia and subjective cognitive complaint. The main questions it aims to answer are: * Whether the eCBTi+ intervention improves sleep (subjective: Insomnia severity index \[ISI\], objective: EEG-based sleep efficiency) sleep and mental health (Geriatric Anxiety Index \[GAI\] and Geriatric Depression S... Read More
Gender:
ALL
Ages:
Between 60 years and 99 years
Trial Updated:
06/05/2025
Locations: The Royal's Institute of Mental Health Research (IMHR), Ottawa, Ontario +1 locations
Conditions: Insomnia
Register for Updates
The STOP-MED CTRCD Trial
NCT06183437
Recruiting
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +9 locations
Conditions: Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Register for Updates
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
NCT06302439
Recruiting
The purpose of this prospective registry is to characterize the natural history of ectonucleotide pyrophosphatase/phosphodiesterase1(ENPP1) Deficiency and the infantile-onset form of adenosine triphosphate (ATP) binding cassette transporter protein subfamily C member 6 (ABCC6) Deficiency longitudinally. The registry will prospectively gather information about the genetic, biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes \[PROs... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/05/2025
Locations: Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois +12 locations
Conditions: ATP-Binding Cassette Subfamily C Member 6 Deficiency, Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency
Register for Updates
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
NCT03981575
Recruiting
Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogen... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/04/2025
Locations: University of California, San Diego, La Jolla, California +16 locations
Conditions: Myotonic Dystrophy 1, DM1
Register for Updates
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
NCT05633459
Recruiting
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2025
Locations: Universitaire Ziekenhuizen Leuven (UZ Leuven), Leuven, Not set +14 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Observational Study Protocol: LIVER-R
NCT06252753
Recruiting
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data colle... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/04/2025
Locations: Research Site, Birmingham, Alabama +112 locations
Conditions: Hepatobiliary Cancers
Register for Updates
Home Initiation of Noninvasive Positive Pressure Ventilation in Children With Medical Complexity
NCT05881031
Recruiting
Children with medical complexity (CMC) often have trouble breathing at night and need to use a breathing machine. This breathing machine is called noninvasive positive pressure ventilation (NiPPV). The use of NiPPV has been shown to improve quality of life and survival in children. Before it is used, NiPPV must first be tested to see what the correct 'machine settings' are for each child. This is usually done in the sleep laboratory at the hospital during a one-night stay. However, sleep studies... Read More
Gender:
ALL
Ages:
Between 60 months and 215 months
Trial Updated:
06/04/2025
Locations: The Hospital for Sick Children, Toronto, Ontario
Conditions: Sleep-Disordered Breathing
Register for Updates
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858
Recruiting
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/04/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona +6 locations
Conditions: Brain Tumor, Non Small Cell Lung Cancer
Register for Updates